Alveo Technologies Is Developing Groundbreaking Avian Influenza Molecular Test for Poultry in Partnership with x-OvO, Royal GD, and Pharmsure
ALAMEDA, Calif., Jan. 9, 2024 /PRNewswire/ -- Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary be.well technology platform, today announced it is working with experts and leaders in the poultry industry to launch a rapid, accurate, in-the-field multiplex panel to test for all relevant strains of avian influenza, initially focusing on Group A, H5, H7, and H9. To help codevelop and distribute the tests, Alveo has partnered with industry leaders x-OvO, Royal GD, and Pharmsure International Ltd. The company expects to release their first product in the poultry diagnostic space, in EMEA in the first half of 2024.
- To help codevelop and distribute the tests, Alveo has partnered with industry leaders x-OvO, Royal GD, and Pharmsure International Ltd.
- The avian flu test will be Alveo's first product to launch into the agricultural sector since Alveo announced its open platform and partnering strategy last year.
- In addition to avian flu, Alveo is partnering to develop test panels for many other pathogens impacting the agriculture industry.
- "We've been working closely with Alveo in a deep collaboration to develop these highly valuable assays for Avian Influenza," said Wim Kieftenbeld, Director Business Development at Royal GD.